University of North Carolina, Chapel Hill
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).
University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.
University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Top-decile sponsor footprint
University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,109 total, page 22 of 23
C2P Mobilization Intervention (Pilot)
NCT00393575
Study of Aripiprazole to Treat Children and Adolescents With Autism
NCT00619190
Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone
NCT00287326
Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating
NCT00618904
Family-based HIV Prevention for Adolescent Girls
NCT00243126
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
NCT00142740
Daily Vitamin K in Patients on Warfarin With Unstable INRs
NCT00287313
Inhalation of 20,000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers
NCT00654134
The Utility of Nexium in Chronic Cough and Reflux Disease
NCT00287339
Surgical Decision Making Among People With Inflammatory Bowel Disease
NCT00438711
Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers
NCT00224900
Immunologic Memory (Supp. of ATN 024)
NCT00142753
The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma
NCT00142610
Early Intervention With Fluoxetine in Autism
NCT00183339
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
NCT00287352
Efficacy and Tolerability of Baclofen for Alcohol Dependence
NCT00877734
Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth
NCT00103532
North Carolina WISEWOMAN: Weight-Wise Pilot Study
NCT00288301
Adolescent Safer Sex Social Network Intervention
NCT00107562
Acupuncture for the Prevention of Postdates Pregnancy
NCT00312585
Albumin Use in Burn Patients
NCT00609414
Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
NCT00924898
Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females
NCT00109421
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
NCT00137176
Preventing Falls Through Enhanced Pharmaceutical Care
NCT00618800
A Couples Approach to Enhance Breast Cancer Survivorship
NCT00665899
Typology of Adherence in Adolescents: Phase II
NCT00106678
Oral Peanut Immunotherapy for Peanut Allergic Patients
NCT01891136
Early Brain Development in Twins
NCT01409746
IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion
NCT00624000
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
NCT00107042
MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk
NCT00097656
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
NCT00106964
Simplified Consent for HIV Vaccine Trials
NCT00105339
Connect to Protect Partnerships for Youth Prevention Interventions: Phase II
NCT00103896
Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults
NCT00838851
Metabolic Abnormalities in HIV Infected and Uninfected Young Women
NCT00067587
Engaging Care for HIV-infected Adolescent Females.
NCT00489034
4-Day-A-Week Treatment Plan for HIV Infected Adolescents
NCT00068809
Reducing Symptoms of Depression in Low-Income Mothers
NCT00074789
NC Enhanced WISEWOMAN Project
NCT00288327
A Novel Method to Determine HIV Incidence Among Youth
NCT00103883
Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)
NCT00597558
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
NCT00107029
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders
NCT01006551
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
NCT00839189
Prospective Studies of the Pathogenesis of Schizophrenia
NCT00877552
Carotid Occlusion Surgery Study
NCT00029146
Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans
NCT00840528
Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00053703
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 111 |
| Phase 2 | 92 |
| Phase 3 | 13 |
| Phase 4 | 56 |
Therapeutic Areas
What is open in the University of North Carolina, Chapel Hill pipeline
108 recruiting of 1,109 indexed (10% open); 881 completed (79%).
Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Obesity (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of North Carolina, Chapel Hill: open-pipeline peers nationwide
Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,109 trials (± recruiting share)
- University of Florida · 1,106 trials · 15% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Ohio University · 10% recruiting · 51 trials
Related
What to do with this University of North Carolina, Chapel Hill page
1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.
- 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.